An senior health figure was recused of involvement in an major research project concerning puberty blockers after claims regarding preconceived views surfaced.
Alleged Involvement Caused Study Halt
As reported by media coverage, Professor Jacob George, a head scientific advisor for the regulatory agency, raised issues that resulted in the pausing of the national Pathways trial in February.
The regulator declared this weekend that the professor was recusing himself of any role in the trial once skeptical social media remarks posted last year were identified.
Content Regarding the Online Posts
In a statement, George referred to author the Harry Potter author being a “treasure of our time.” Separately, he commented that the rejection of basic biological fact is concerning” in regards to questions about an elite athlete’s gender.
This agency said how although George’s comments were made before his official position, he had been recused from involvement in the study as a preventative measure.
Details of the Halted Clinical Study
This Pathways trial, that was designed to evaluate the impact from hormone suppressants for children questioning their gender identity, was set to begin recruiting volunteers during January.
However, it was halted during February once the regulatory body expressed concerns regarding the welfare of adolescents participating.
- The youngest subjects were anticipated to be 10 to 11 among assigned female at birth while 11 to 12 for biological males.
- The study team stated earlier how the thorough selection procedure indicated those enrolled would almost certainly be older.
- But, the agency have since stated the lowest age threshold must be 14 because of an uncertain potential” of “long-term health consequences.”
The study was designed to include an estimated 226 young people over the coming several years.
Background and a Cass Review
This study was commissioned after an urging from an independent inquiry into children’s gender care, that found that the quality of studies suggesting to demonstrate the benefits from this type of treatment for youngsters with gender incongruence were weak.”
Doctor Hilary Cass, who chaired the review, had earlier commented her findings “uncovered a very weak evidence base” for the usefulness of such treatments.
She continued, considering that there exist clinicians, young people as well as families who believe strongly of the helpful results, a study remained the only way ahead to make sense of the situation.”
Medical Criticism of the Decision
Dr Max Davie, a consultant paediatrician, said there was no convincing medical rationale to pause the study.
“The tweets from Prof George give a clear indication of his personal views on the topic,” he said. “The professor is entitled to possess whatever views about gender identity he wishes, however what he cannot do is allow these beliefs to affect the performance of his regulatory responsibilities.”
He concluded: “To be clear, there is no compelling research justification to pause this study. Although the professor’s own views are not the sole potential reason of the MHRA’s abrupt reversal, they is the sole instance for which we have proof.”
Agency Response Regarding Next Steps
A MHRA representative commented: “With every clinical trials, the MHRA’s primary concern is the protection as well as wellbeing for the volunteers. As part of this duty, complex studies are kept continuously under review while the agency maintains an active discussion with trial sponsors.”
“We have expert scientific, medical and oversight specialists that operate in a cross-functional group to provide research-informed rulings regarding medical research. These experts will continue to work alongside the university to work through the subsequent actions in a positive manner.”
“Subsequent to the identification of online posts made prior to his tenure began, Prof Jacob George is recused of continued involvement on the Pathways study as an abundance of caution.”